Breaking News Instant updates and real-time market news.

MLHR

Herman Miller

$37.95

-0.55 (-1.43%)

, KNL

Knoll

$23.14

1.1 (4.99%)

10:25
12/26/17
12/26
10:25
12/26/17
10:25

On The Fly: Top five analyst actions

Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MLHR

Herman Miller

$37.95

-0.55 (-1.43%)

KNL

Knoll

$23.14

1.1 (4.99%)

UTL

Unitil

$45.42

1.1 (2.48%)

AGRX

Agile Therapeutics

$2.52

-2.24 (-47.06%)

RXDX

Ignyta

$26.85

11.3 (72.67%)

RHHBY

Roche

$31.13

0.07 (0.23%)

  • 26

    Dec

  • 23

    Feb

MLHR Herman Miller
$37.95

-0.55 (-1.43%)

12/26/17
RAJA
12/26/17
UPGRADE
Target $43
RAJA
Outperform
Herman Miller upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Budd Bugatch upgraded Herman Miller to Outperform and established a $43 price target following newly passed tax reform. The analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases given immediate expensing of short-term capital assets.
06/27/17
SIDC
06/27/17
INITIATION
Target $38
SIDC
Buy
Herman Miller initiated with a Buy at Sidoti
Sidoti analyst Gregory Burns started Herman Miller with a Buy rating and $38 price target.
03/23/17
03/23/17
UPGRADE

Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
As previously reported, Raymond James upgraded Herman Miller to Market Perform from Underperform. Analyst Budd Bugatch views risk/reward a more balanced following the Q3 report.
03/23/17
RAJA
03/23/17
UPGRADE
RAJA
Market Perform
Herman Miller upgraded to Market Perform from Underperform at Raymond James
KNL Knoll
$23.14

1.1 (4.99%)

08/16/17
SIDC
08/16/17
INITIATION
SIDC
Buy
Knoll initiated with a Buy at Sidoti
Sidoti initiated Knoll with a Buy and a $28 price target.
12/26/17
RAJA
12/26/17
UPGRADE
Target $26
RAJA
Strong Buy
Knoll upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Budd Bugatch upgraded Knoll and raised its price target to $26 from $23 following the enactment of US tax reform. The analyst believes Knoll's sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve.
08/28/17
08/28/17
UPGRADE

Outperform
Knoll upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded Knoll to Outperform from Market Perform and established a $20 price target. Analyst Budd Bugatch views valuation as attractive and said Knoll is well positioned to drive revenue growth as the macro environment for office furniture normalizes given an increased sales force, new product offerings, and competitive pricing.
08/28/17
RAJA
08/28/17
UPGRADE
RAJA
Outperform
Knoll upgraded to Outperform from Market Perform at Raymond James
UTL Unitil
$45.42

1.1 (2.48%)

12/18/17
BOFA
12/18/17
INITIATION
Target $49
BOFA
Neutral
Unitil initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin- initiated Unitil Corp. with a Neutral and $49 price target saying consensus estimates are too high and expects growth to be more in line with current ratebase trends.
12/26/17
JANY
12/26/17
UPGRADE
Target $50
JANY
Buy
Unitil upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Michael Gaugler upgraded Unitil to Buy citing "compelling" valuation and lowered its price target to $50 from $52.
AGRX Agile Therapeutics
$2.52

-2.24 (-47.06%)

12/22/17
JANY
12/22/17
DOWNGRADE
JANY
Neutral
Agile Therapeutics downgraded to Neutral from Buy at Janney Capital
12/26/17
WBLR
12/26/17
DOWNGRADE
WBLR
Market Perform
Agile Therapeutics downgraded to Market Perform at William Blair
William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. The analyst thinks the issues raised by the FDA may be addressable but has concerns regarding management's execution of the company's lead product.
12/26/17
NEED
12/26/17
NO CHANGE
Target $14
NEED
Buy
Corium price target lowered to $14 from $16 at Needham
Needham analyst Serge Belanger lowered his price target on Corium (CORI) to $14 after the FDA's letter on the Twirla contraceptive patch by Agile Therapeutics (AGRX) outlined its deficiencies. Belanger says Twirla was Corium's most near-term revenue opportunity, pushing out its anticipated approval by about 12 months. The analyst keeps his Buy rating on Corium.
12/26/17
JEFF
12/26/17
NO CHANGE
Target $13
JEFF
Buy
Corium's partner's CRL looks addressable, says Jefferies
Jefferies analyst David Steinberg believes the complete repose letter received by Corium's (CORI) partner Agile Therapeutics (AGRX) appears addressable. Management indicated the issues relate to Agile's use of standard square-patch tests to assess its circular patch, Steinberg tells investors in a research note. They believe the adhesion profile is "excellent" and, importantly, data addressing the issue has not yet been reviewed by the FDA, the analyst adds. He notes that Twirla's profitability impact to Corium is relatively low, causing only a modest reduction in out-year estimates from the delayed approval. Steinberg keeps a Buy rating on Corium with a $13 price target.
RXDX Ignyta
$26.85

11.3 (72.67%)

12/22/17
JEFF
12/22/17
DOWNGRADE
Target $27
JEFF
Hold
Ignyta downgraded to Hold from Buy at Jefferies
Jefferies analyst Maury Raycroft downgraded Ignyta (RXDX) to Hold after the company reached an agreement to be acquired by Roche (RHHBY). The analyst maintains a $27 price target for shares.He expects the deal to close.
12/22/17
STFL
12/22/17
NO CHANGE
STFL
Buy
Roche deal has postive read-through for Loxo Oncology, says Stifel
Stifel analyst Stephen Willey anticipates bears will say Roche's (RHHBY) deal for Ignyta (RXDX) reflects the potential competitiveness of Ignyta's entrectinib relative to Loxo Oncology's (LOXO) larotrectinib in malignancies caused by NTRK fusions. However, he is "firmly" in the bull camp that Roche's acquisition was primarily focused around the opportunity for entrectinib in treating ROS-1 fusions in NSCLC and that this deal reflects big pharma's appetite for targeted agents and long-duration oncology assets. Willey has a Buy rating on Loxo shares.
12/26/17
LTCO
12/26/17
DOWNGRADE
LTCO
Neutral
Ignyta downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded Ignyta (RXDX) to Neutral after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
12/26/17
RHCO
12/26/17
DOWNGRADE
RHCO
Hold
Ignyta downgraded to Hold from Buy at SunTrust
SunTrust downgraded Ignyta (RXDX) to Hold after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
RHHBY Roche
$31.13

0.07 (0.23%)

12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Overweight
Roche to outperform on 'very strong' lung cancer data, says JPMorgan
JPMorgan analyst Richard Vosser says Roche reported "very strong" detailed progression free survival data from its IMPower150 lung cancer study. At the conference later today, the analyst expects to see strong interim overall survival data. He expects the shares to outperform by 1%-2% following this morning's data. Vosser has an Overweight rating on Roche.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.

TODAY'S FREE FLY STORIES

CBS

CBS

$51.75

0.14 (0.27%)

21:20
05/20/18
05/20
21:20
05/20/18
21:20
Upgrade
CBS rating change at Bernstein »

CBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$40.63

0.89 (2.24%)

20:40
05/20/18
05/20
20:40
05/20/18
20:40
Upgrade
Knight-Swift rating change at Stifel »

Knight-Swift upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

, FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

19:24
05/20/18
05/20
19:24
05/20/18
19:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

CBS

CBS

$51.75

0.14 (0.27%)

ROKU

Roku

$35.40

1.14 (3.33%)

LOW

Lowe's

$86.31

0.85 (0.99%)

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 22

    May

  • 23

    May

  • 12

    Jun

JHG

Janus Henderson Group

$32.43

-0.3 (-0.92%)

18:38
05/20/18
05/20
18:38
05/20/18
18:38
Hot Stocks
Janus Henderson Group announces dividend of 36c »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHG

Philips

$43.01

0.26 (0.61%)

17:29
05/20/18
05/20
17:29
05/20/18
17:29
Hot Stocks
New data shows combined COPD treatments could help reduce annual cost of care »

At the American Thoracic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.26

1.37 (1.47%)

, CMCSA

Comcast

$32.72

0.3 (0.93%)

16:45
05/20/18
05/20
16:45
05/20/18
16:45
Hot Stocks
Box Office Battle: 'Deadpool 2' debuts at number 1 with $125M »

Ryan Reynolds and…

TWX

Time Warner

$94.26

1.37 (1.47%)

CMCSA

Comcast

$32.72

0.3 (0.93%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$48.60

-0.2 (-0.41%)

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

LGF.A

Lionsgate

$24.27

0.3 (1.25%)

DIS

Disney

$103.94

-0.4 (-0.38%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TSLA

Tesla

$276.84

-7.6 (-2.67%)

16:28
05/20/18
05/20
16:28
05/20/18
16:28
Periodicals
ISS recommending Tesla shareholders split chairman, CEO role, Bloomberg says »

The largest proxy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:23
05/20/18
05/20
16:23
05/20/18
16:23
Periodicals
China agrees to import more from U.S., no sign of $200B target, Reuters says »

China has agreed to…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.98

-0.05 (-0.33%)

, WAB

Wabtec

$95.23

1.1 (1.17%)

16:19
05/20/18
05/20
16:19
05/20/18
16:19
Periodicals
GE nearing deal to merge transportation unit with Wabtec, Reuters says »

General Electric (GE) is…

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 12

    Jun

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:17
05/20/18
05/20
16:17
05/20/18
16:17
Periodicals
Trump administration walks back Chinese tariff plans, Axios says »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$77.47

0.965 (1.26%)

16:13
05/20/18
05/20
16:13
05/20/18
16:13
Hot Stocks
Dillard's announces 10c cash dividend »

Dillard's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$6.45

-0.07 (-1.07%)

16:11
05/20/18
05/20
16:11
05/20/18
16:11
Hot Stocks
Data shows 'real-world' value of Afirma GSC in thyroid cancer diagnosis »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

, MSCC

Microsemi

$68.60

(0.00%)

15:42
05/20/18
05/20
15:42
05/20/18
15:42
Conference/Events
Microsemi to host special shareholder meeting »

Special shareholder…

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

MSCC

Microsemi

$68.60

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDNG

Hardinge

$18.44

0.03 (0.16%)

15:35
05/20/18
05/20
15:35
05/20/18
15:35
Conference/Events
Hardinge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

15:30
05/20/18
05/20
15:30
05/20/18
15:30
Conference/Events
Bravo Brio Restaurant to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.